{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:29Z","timestamp":1789185569572,"version":"build-2803163510"},"reference-count":114,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":735,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p>Resistance to antibiotics among gram\u2010positive bacteria, especially enterococci and staphylococci, has led to the need to develop new antibiotics. Vancomycin, a glycopeptide antibiotic, has been used for over 3 decades to treat serious methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections. The increased frequency of multidrug\u2010resistant bacteria, especially vancomycin\u2010resistant strains, has focused interest on three new lipoglycopeptides for the treatment of infections caused by gram\u2010positive bacteria: oritavancin, dalbavancin, and telavancin. Although oritavancin and dalbavancin are still in development, telavancin received approval from the United States Food and Drug Administration in September 2009 for treatment of complicated skin and skin structure infections. Structurally different from vancomycin and teicoplanin, all three lipoglycopeptides have greater potency and less potential for development of resistant organisms. Of particular importance is the activity of oritavancin, dalbavancin, and telavancin against vancomycin\u2010resistant organisms. In addition, the pharmacokinetic properties of these new antimicrobials substantially differ from those of vancomycin. Both oritavancin and dalbavancin have long terminal half\u2010lives, which may allow for infrequent dosing. In addition, oritavancin is primarily cleared through hepatic pathways, which makes it potentially useful in patients with renal compromise. In animal models, these new lipoglycopeptides were effective in treating serious gram\u2010positive infections, including complicated skin and skin structure infections, endocarditis, bacteremia, and pneumonia; in clinical studies, however, efficacy was shown only in complicated skin and skin structure infections for all three agents. According to preliminary data, the adverse\u2010effect profile of these lipoglycopeptides is generally similar to that of drugs currently used to treat severe gram\u2010positive infections. However, further evaluation and monitoring is necessary as more patients are exposed to these agents. As antimicrobial resistance continues to increase worldwide, the lipoglycopeptides may provide clinicians with a useful antimicrobial in the continued fight against multidrug\u2010resistant gram\u2010positive bacteria.<\/jats:p>","DOI":"10.1592\/phco.30.1.80","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T09:09:15Z","timestamp":1261559355000},"page":"80-94","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin"],"prefix":"10.1002","volume":"30","author":[{"given":"Michael T.","family":"Guskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Infectious Diseases Society of America.Bad bugs no drugs as antibiotic discovery stagnates\u2026 a public health crisis brews. Available fromhttp:www.idsociety.orgWorkAreashowcontent.aspxid5554. Accessed October 29 2008."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400701"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_2_1_5_2","unstructured":"Targanta Therapeutics Corporation.Pipeline: oritavancin program.2008. Available from:http:www.targanta.compipelineoritavancin.html. Accessed September 6 2008."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(03)00120-0"},{"key":"e_1_2_1_7_2","unstructured":"Pfizer Inc.Pfizer receives approvable letter from FDA for dalbavancin. December 21 2007. Available fromhttp:mediaroom.pfizer.comportalsitepfizerindex.jspndmViewIdnews_view&newsId20071221005672&newsLangen. Accessed September 6 2008."},{"key":"e_1_2_1_8_2","unstructured":"Pfizer Inc.Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. September 6 2008. Available fromhttp:www.pfizer.beMediaPressbulletinsResearchanddevelopmentandbusinessdevelopmentWithdrawdalbavancinmarketapplications.htm. Accessed September 6 2008."},{"key":"e_1_2_1_9_2","unstructured":"Theravance Inc. and Astellas Pharma US Inc.Theravance receives FDA approvable letter for telavancin for the treatment of complicated skin and skin structure infections.October 22 2007. Available fromhttp:ir.theravance.comReleaseDetail.cfmReleaseID270328. Accessed September 6 2008."},{"key":"e_1_2_1_10_2","unstructured":"Theravance Inc.Theravance reports favorable outcome of FDA advisory committee meeting on telavancin for the treatment of complicated skin and skin structure infections. November 19 2008. Available fromhttp:ir.theravance.comReleaseDetail.cfmReleaseID348983. Accessed February 16 2009."},{"key":"e_1_2_1_11_2","unstructured":"Theravance Inc.Theravance submits U.S. NDA for telavancin for the treatment of hospital\u2010acquired pneumonia. January 26 2009. Available fromhttp:ir.theravance.comReleaseDetail.cfmReleaseID361466. Accessed February 16 2009."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.04.006"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.781"},{"key":"e_1_2_1_14_2","volume-title":"Current medicinal chemistry","author":"Malabarba A","year":"2001"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/AAC.41.11.2418","article-title":"Semiquantitation of cooperativity in binding of vancomycin\u2010group antibiotics to vancomycin\u2010susceptible and\u2010resistant organisms","volume":"41","author":"Beauregard D","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_17_2","volume-title":"Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin\u2010resistant enterococci","author":"McKay G","year":"2007"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.08.067"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_2_1_20_2","volume-title":"Probing the mechanism of inhibition of bacterial peptidoglycan glycosyltransferases by glycopeptide analogs","author":"Wang T","year":"2007"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","article-title":"Moderate\u2010level resistance to glycopeptide LY333328 mediated by genes of the van A and van B clusters in enterococci","volume":"43","author":"Arthur M","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02368-06"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.179"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.4033-4036.2004"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00286-06"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313020600820732"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/AAC.41.2.488","article-title":"In vitro activity and spectrum of LY333328, a novel glycopeptide derivative","volume":"41","author":"Jones R","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.08.015"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh156"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm211"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.03.004"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1370-1374.2000"},{"key":"e_1_2_1_37_2","volume-title":"In vitro susceptibility of genotypically distinct clostridium difficile strains to oritavancin","author":"O'Conner R","year":"2007"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.4.417"},{"key":"e_1_2_1_39_2","volume-title":"Activity of oritavancin against drug\u2010resistant Staphylococcus aureus in the presence of polysorbate\u201080","author":"Arhin F","year":"2007"},{"key":"e_1_2_1_40_2","unstructured":"ArhinF SarmientoI ParrTR MoeckG.Effect of polysorbate\u201080 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Presented at the 17th European congress of clinical microbiology and infectious diseases Munich Germany March 31-April 3 2007."},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl311"},{"key":"e_1_2_1_42_2","first-page":"229","article-title":"Dalbavancin (Biosearch Italia\/Versicor)","volume":"3","author":"Steiert M","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02411-06"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.12.2197"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3602-3604.2003"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2149-2152.2004"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.148-152.2005"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm263"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280378"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.788-790.2006"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600800621"},{"key":"e_1_2_1_55_2","volume-title":"Population pharmacokinetic model","author":"Owen J","year":"2003"},{"key":"e_1_2_1_56_2","volume-title":"The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment","author":"Dowell J","year":"2004"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn273"},{"key":"e_1_2_1_58_2","volume-title":"Protein binding of14 C\u2010oritavancin","author":"Rowe P","year":"2001"},{"key":"e_1_2_1_59_2","volume-title":"Protein binding of dalbavancin using isothermal titration microcalorimetry","author":"Cavaleri M","year":"2002"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_2_1_61_2","volume-title":"Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (in healthy men)","author":"Chien J","year":"1999"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.940-945.2004"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.06.007"},{"key":"e_1_2_1_64_2","volume-title":"The pharmacokinetics and renal excretion of dalbavancin in healthy subjects","author":"Dowell JA","year":"2002"},{"key":"e_1_2_1_65_2","volume-title":"Study ARKK","author":"Thomasson H","year":"1997"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01264-06"},{"key":"e_1_2_1_67_2","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.42.10.2564","article-title":"Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin\u2010resistant Enterococcus faecium.","volume":"42","author":"Baltch AL","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf058"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390060137031"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00132-6"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_2_1_72_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1128\/AAC.41.6.1307","article-title":"Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.","volume":"41","author":"Mercier R","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"e_1_2_1_74_2","doi-asserted-by":"crossref","unstructured":"ZinnerS StrukovaE SmirnovaM LubenkoI VostrovS FirsovA.Bacterial strain\u2010independent anti\u2010staphylococcal effects of telavancin in an in vitro dynamic model that simulates multiple\u2010dose pharmacokinetics in humans. Presented at the European society of clinical microbiology and infectious diseases. Munich Germany March 31-April 3 2007.","DOI":"10.1016\/S0924-8579(07)71901-5"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.4.519"},{"key":"e_1_2_1_76_2","volume-title":"In vitro post antibiotic effect studies of oritavancin against S. aureus and enterococci","author":"Belley A","year":"2007"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.6.1047"},{"key":"e_1_2_1_78_2","volume-title":"Oritavancin kills Staphylococcus aureus in slow\u2010growing planktonic and biofilm states","author":"Belley A","year":"2006"},{"key":"e_1_2_1_79_2","volume-title":"Pharmacokinetic concentrations of oritavancin kill stationary\u2010phase and biofilm Staphylococcus aureus in vitro","author":"Belley A","year":"2007"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.006"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki198"},{"key":"e_1_2_1_82_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.43.3.592","article-title":"Synergy of an investigational glycopeptide, LY333328, with once\u2010daily gentamicin against vancomycin\u2010resistant Enterococcus faecium in a multiple\u2010dose, in vitro pharmacodynamic model","volume":"43","author":"Zelenitsky SA","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.283"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00361-08"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.12.015"},{"key":"e_1_2_1_86_2","volume-title":"Interaction of telavancin and other antimicrobial agents tested against key gram\u2010positive species","author":"Sahm D","year":"2006"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00620-06"},{"key":"e_1_2_1_89_2","volume-title":"Telavancin demonstrates a low potential for in vitro selection of resistance among key target gram\u2010positive species","author":"Sahm DF","year":"2006"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.705"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1907-1911.2003"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2169-2172.2001"},{"key":"e_1_2_1_93_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.42.4.981","article-title":"Efficacy of LY333328 against experimental methicillin\u2010resistant Staphylococcus aureus endocarditis","volume":"42","author":"Kaatz GW","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_94_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.43.1.115","article-title":"Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin\u2010resistant Enterococcus faecalis.","volume":"43","author":"Saleh\u2010Mghir A","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3017-3021.2000"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm417"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4344-4346.2005"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl222"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.770-773.2006"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01266-06"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3163-3165.2005"},{"key":"e_1_2_1_102_2","unstructured":"YinLY CalhounJ ThomasT WirtzE.Comparative efficacies of telavancin vancomycin and linezolid in a rabbit model of methicillin\u2010resistantStaphylococcus aureusosteomyelitis. Presented at the European congress of clinical microbiology and infectious diseases. Munich Germany March 31-April 3 2007."},{"key":"e_1_2_1_103_2","unstructured":"Targanta Therapeutics Corporation.8\u2010K exhibit 99.1. 2008. Available fromhttp:yahoo.brand.edgar\u2010online.comdisplayfilinginfo.aspxFilingID6195294\u20105391\u201010858&typesect&dcn0001193125\u201008\u2010210576. Accessed October 23 2008."},{"key":"e_1_2_1_104_2","volume-title":"Equivalence of shorter course therapy with oritavancin compared to vancomycin\/cephalexin in complicated skin\/skin structure infections","author":"Wasilewski M","year":"2001"},{"key":"e_1_2_1_105_2","volume-title":"Phase III trial comparing 3\u20137 days of oritavancin versus 10\u201314 days of vancomycin\/cecphalexin in the treatment of patients with skin\/skin structure infections (CSSI)","author":"Giamarello H","year":"2003"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1086\/379015"},{"key":"e_1_2_1_107_2","volume-title":"Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy","author":"Goldstein B","year":"2005"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1086\/429914"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_2_1_113_2","unstructured":"United States National Library of Medicine National Institutes of Health.Comparison of telavancin and vancomycin for hospital\u2010acquired pneumonia due to methicillin\u2010resistantStaphylococcus aureus(ATTAIN 1).2007. Available fromhttp:clinicaltrials.govct2showNCT00107952. Accessed February 16 2009."},{"key":"e_1_2_1_114_2","unstructured":"United States National Library of Medicine National Institutes of Health.Comparison of telavancin and vancomycin for hospital\u2010acquired pneumonia due to methicillin\u2010resistantStaphylococcus aureus(ATTAIN 2).2007. Available fromhttp:clinicaltrials.govct2showNCT00124020termATTAIN2&rank1. Accessed February 16 2009."},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.09.004"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.1.80","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.1.80","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:33:42Z","timestamp":1761046422000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.1.80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1592\/phco.30.1.80"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.1.80","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}